Ultrastructural cytochemical prospective study of adult acute lymphoblastic leukemia: Detection of peroxidase activity in patients failing to respond to treatment
✍ Scribed by Josy Reiffers; Vivianne Darmendrail; Jacky Larrue; Isabelle Villenave; Philippe Bernard; Michel Boisseau; Antoine Broustet
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- English
- Weight
- 437 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Ultrastructural cytochemical studies revealed peroxidase activity in five of 25 adult patients with apparent null lymphoblastic leukemia (ALL) in whom the peroxidase reaction studied with light microcopy was negative. None of these 5 patients responded to a chemotherapy regimen used for adult ALL. The importance of ultrastructural cytochemistry which allows the recognition of myeloblastic differentiation in undifferentiated blast cells is also demonstrated. The correct classification of such cases may be important for prognosis because they appear to be resistant to the chemotherapy used in treating ALL.
Cancer 48:927-931, 1981.
H E MYELOPEROXIDASE REACTION is commonly
T used in establishing cytologic diagnosis of acute leukemia, and especially in distinguishing myeloblastic leukemia type M, from lymphoblastic leukemia type L,.' Generally, myeloperoxidase is easily recognized in myeloblastic leukemias, however, in some nongranular forms, it may only be demonstrated by ultrastructural cytochemistry.5-14 Authentic myeloblastic forms may thus be incorrectly labeled and treated as lymphoblastic leukemias. In order to judge the frequency of this phenomenon, we systematically searched for peroxidatic activity with transmission electron microscopy (TEM) in 25 adult patients each time that the myeloperoxidase reaction was negative with light microscopy (LM). The results are analyzed and compared to the FAB cytologic classification' and retrospectively to the patients' responses to chemotherapy.
From the Department of Internal Medicine and Blood Diseases, *.